Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Total Non-Current Liabilities data on file, last reported at $123.0 million in Q4 2023.

• Total Non-Current Liabilities for Q4 2023 came in at $123.0 million, down 70.54% year-over-year; the trailing twelve-month figure through Dec 2023 was $123.0 million (down 70.54% YoY), and the FY2023 annual result was $123.0 million, down 70.54% from the prior year.
• Total Non-Current Liabilities rose to $123.0 million in Q4 2023 per DNLI's latest filing, from $118.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $453.0 million in Q4 2020 and troughed at $118.1 million in Q3 2023.
• A 5-year average of $289.1 million and a median of $295.0 million in 2020 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2023: Total Non-Current Liabilities jumped 201.41% in 2021, then sank 71.61% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $158.0 million in 2019, then jumped by 186.81% to $453.0 million in 2020, then declined by 2.55% to $441.5 million in 2021, then retreated by 5.45% to $417.4 million in 2022, then plunged by 70.54% to $123.0 million in 2023.
• Business Quant data shows DNLI's Total Non-Current Liabilities at $123.0 million in Q4 2023, $118.1 million in Q3 2023, and $118.5 million in Q2 2023.